株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

カナダのジェネリック医薬品市場

Generic Drug Market in Canada

発行 RNCOS E-Services Pvt. Ltd. 商品コード 223495
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
カナダのジェネリック医薬品市場 Generic Drug Market in Canada
出版日: 2011年11月01日 ページ情報: 英文 65 Pages
概要

2010年に、ジェネリック医薬品カナダで処方された薬品の57%以上、そして医薬品市場全体の26%を占めるようになりました。ブランド医薬品の特許失効や高齢化の進展、医療費支出削減のための政府の支援などを受けて、カナダのジェネリック薬品市場は2011〜2014年に年平均で約13%の成長を遂げると予想されています。

当レポートでは、カナダにおけるジェネリック医薬品(後発医薬品)市場について分析し、全体的な市場構造や、最新の市場動向、地域別・部門別・疾患別の市場動向の実績値・予測値、政府の規制・政策、主要企業プロファイルなどの情報を盛り込んで、概略以下の構成でお届けします。

第1章 アナリストの見解

第2章 マクロ経済および医療関係要因

  • マクロ経済指標
  • 人口プロファイル
  • 年齢プロファイル
  • 医療費支出およびインフラ

第3章 市場動向

  • 高血圧用のジェネリック医薬品の増加
  • ジェネリック医薬品の価格低下
  • 特許失効

第4章 ジェネリック市場の実績

  • 市場規模と成長率
    • 処方件数
    • 売上高
  • 州・準州別
    • 医薬品消費量
    • 処方件数
    • 売上高
  • 流通形態別
    • 小売薬局
    • 病院内の薬局
    • 認可/独立系ジェネリック医薬品
    • 流通経路の比率
  • 疾患別
    • 心血管治療薬
    • 精神病治療薬
    • コレステロール用医薬品
    • 神経症用医薬品
    • 抗糖尿病薬

第5章 規制環境

第6章 競争環境

  • 市場構造
  • 主要企業の分析
    • Apotex
    • Teva Canada Ltd. (Novopharm)
    • Mylan
    • Pharmascience

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Canada is one of the world's largest pharmaceutical markets, even though it has a low share of only 3% in global pharma industry. In 2010, generics accounted for more than 57% prescriptions and around 26% sales of the total pharmaceutical market. On the back of factors including patent expiration of branded drugs, growing aging population, and government support through cost reduction measures, it is estimated that the market for generic drugs will be growing at a CAGR of around 13% during 2011-2014.

According to our latest market research report entitled, “Generic Drug Market in Canada”, the provincial governments are implementing necessary steps to ensure the availability of drugs at an affordable cost. With billion dollars drug patents on the verge of expiry, the generic industry is foreseen to undergo a massive growth in the future. Besides, the government is adopting measures to enhance the supply proportion of generic drugs and rebates offered (to pharmacies) will augment revenue patterns of this industry.

Our report has identified that, neurological disorder therapy has shown an aggressive growth of 7.2% in 2010 over 2009, in terms of total prescription and the amount of prescriptions. However, oncology remained at the top position in terms of hospital sales with CAD 863.4 Million revenue in 2010, whereas the cardiovascular drugs have moved out from the list of top ten sales. Other therapy areas, such as anti-cholesterol agents and hypertension are expected to drive the generics market in Canada in future.

This report was compiled by considering all the requisite ingredients of Canadian generics sector and distinguishes domestic market from other generics market in all possible ways. The Canada generics market constitutes higher prices of generics and lower price erosion, in comparison to the US and most European markets, which makes it a major issue of concern for the government. However, the latest regulatory mechanism clearly shows that the Canadian Government has been adopting measures to ensure optimum generic costs.

“Generic Drug Market in Canada” provides extensive research and objective analysis of the generic drug market in Canada. The report effectively evaluates all the factors that are driving the growth and studies current market trends that will shape the future of the industry. The report also has cited the distribution of the drugs and presented state-wise consumptions to depict a much clear picture of the market. The report also examines the performance of various players in the Canadian pharmaceutical and generic markets. Besides, a number of factors that can prove to be deteriorative for the future growth of market have been discussed in the report.

Table of Contents

1. Analyst View

2. Macroeconomic and Healthcare Factors

  • 2.1. Macroeconomic Indicators
  • 2.2. Population Profile
  • 2.3. Age Profile
  • 2.4. Healthcare Spending and Infrastructure

3. Market Trends

  • 3.1. More Generic Drugs for Hypertension
  • 3.2. Generics Getting Affordable
  • 3.3. Patent Expiration

4. Generics Market Performance

  • 4.1. Market Size and Growth
    • 4.1.1. Prescriptions
    • 4.1.2. Sales
  • 4.2. By Province/Territories
    • 4.2.1. Drug Consumption
    • 4.2.2. Prescriptions
    • 4.2.3. Sales
  • 4.3. By Distribution
    • 4.3.1. Retail Pharmacies
    • 4.3.2. Hospital Pharmacies
    • 4.3.3. Authorized and Independent Generics
    • 4.3.4. Distribution Channels
  • 4.4. By Disease
    • 4.4.1. Cardiovascular Drugs
    • 4.4.2. Psychotherapeutics
    • 4.4.3. Cholesterol Agents
    • 4.4.4. Neurological Agents
    • 4.4.5. Antidiabetics

5. Regulatory Environment

6. Competitive Landscape

  • 6.1. Market Structure
  • 6.2. Key Players Analysis
    • 6.2.1. Apotex
    • 6.2.2. Teva Canada Ltd. (Novopharm)
    • 6.2.3. Mylan
    • 6.2.4. Pharmascience

List of Figures:

  • Figure 2-1: Nominal GDP (Billion US$), 2008-2010
  • Figure 2-2: Consumer Price Index (%), 2010-2014
  • Figure 2-3: Population (Million), 2010-2014
  • Figure 2-4: Life Expectancy (Years), 2010-2014
  • Figure 2-5: Population Breakup by Age Group (%), 2010-2014
  • Figure 2-6: Per Head Healthcare Spending (US$), 2010-2014
  • Figure 2-7: Number of Doctors (2010-2014)
  • Figure 2-8: Number of Hospital Beds (per ‘000 Population), 2010-2014
  • Figure 4-1: Pharmaceutical Sales (Billion CAD), 2010-2014
  • Figure 4-2: Prescriptions Dispensed in Branded Drugs Market (Million), 2006-2010
  • Figure 4-3: Prescriptions Dispensed in Generic Drugs Market (Million), 2006-2010
  • Figure 4-4: Share of Generic and Branded Drugs by Prescription (2006-2010)
  • Figure 4-5: Average Retail Price of Generic and Branded Drugs (CAD), 2006-2010
  • Figure 4-6: Generic Drug Sales (Billion CAD), 2010-2014
  • Figure 4-7: Branded Drug Sales (Billion CAD), 2010-2014
  • Figure 4-8: Share of Generic and Branded Drugs by Sales (2010-2014)
  • Figure 4-9: Branded Drug Sales through Retail Pharmacies (Billion CAD), 2010-2014
  • Figure 4-10: Generic Drug Sales through Retail Pharmacies (Billion CAD), 2010-2014
  • Figure 4-11: Share of Generic and Branded Drug Sales through Retail Pharmacies (2010-2014)
  • Figure 4-12: Branded Drug Sales through Hospital Pharmacies (Billion CAD), 2010-2014
  • Figure 4-13: Generic Drug Sales through Hospital Pharmacies (Billion CAD), 2010-2014
  • Figure 4-14: Share of Generic and Branded Drug Sales through Hospital Pharmacies (2010-2014)
  • Figure 4-15: Share of Independent Generic and Authorized Generic Prescriptions (2005-2008)
  • Figure 4-16: Generic Drugs Market by Retail and Hospital Sales (%), 2010
  • Figure 4-17: Cardiovascular Drug Market (Billion CAD), 2010-2014
  • Figure 4-18: Psychotherapeutics Market (Billion CAD), 2010-2014
  • Figure 4-19: Cholesterol Agents Market (Billion CAD), 2010-2014
  • Figure 4-20: Neurological Agents Market (Billion CAD), 2010-2014
  • Figure 4-21: Number of Diabetes Patients in Age Group 20-79 Years (Million), 2010 & 2030
  • Figure 4-22: Diabetes Therapy Market (Million CAD), 2010-2014

List of Tables:

  • Table 3-1: Patent Expiration for Some Hypertension Drugs (2012)
  • Table 3-2: Patent Expiration of Key Drugs (2012)
  • Table 4-1: Top Ten Therapy Areas by Prescription (‘000), 2010
  • Table 4-2: Per Capita Drug Spending of Public and Private Sector by Region (CAD), 2010
  • Table 4-3: Generic Drug Prescriptions Dispensed by Region (%), 2006-2010
  • Table 4-4: Generic Drug Sales by Region (%), 2006 & 2010
  • Table 4-5 Top Ten Therapy Areas by Retail Pharmacy Sales (Billion CAD), 2010
  • Table 4-6: Number of Retail Pharmacies by Category (2006-2011)
  • Table 4-7: Top Ten Therapy Areas by Hospital Sales (Million CAD), 2010
  • Table 6-1: Top Pharmaceutical Companies by Sales (Billion CAD), 2010
  • Table 6-2: Top Generic Drug Companies by Prescription (Million), 2007
  • Table 6-3: Top Generic Drug Companies by Sales (Million CAD), 2007
  • Table 6-4: Apotex - Strengths & Weaknesses
  • Table 6-5: Teva Canada Ltd. (Novopharm) - Strengths & Weaknesses
  • Table 6-6: Mylan - Strengths & Weaknesses
Back to Top